Rituximab® and high dose methylprednisolone (HDMP) as a first line treatment for patients with chronic lymphocytic leukemia

被引：0
|
作者：
Castro, JE
Bole, JE
Prada, CE
Loria, O
Kipps, TJ
机构：
[1] Univ Calif San Diego, John & Rebecca Moores Canc Ctr, La Jolla, CA 92093 USA
[2] Chron Lymphocyt Leukemia Res Consortium, San Diego, CA USA
来源：
BLOOD | 2005年 / 106卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2969
引用
收藏
页码：833A / 833A
页数：1
相关论文
共 50 条
  • [31] Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma
    Hainsworth, John D.
    Vazquez, Elizabeth R.
    Spigel, David R.
    Raefsky, Eric
    Bearden, James D.
    Saez, Ruben A.
    Greco, F. Anthony
    CANCER, 2008, 112 (06) : 1288 - 1295
  • [32] DOSE DENSE HIGH DOSE METHYLPREDNISOLONE (HDMP) AND RITUXIMAB (RTX) ARE EFFECTIVE IN RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH 17P DELETION (17P DEL) / TP53 MUTATION
    Pileckyte, R.
    Valceckiene, V.
    Zvirblis, T.
    Griskevicius, L.
    HAEMATOLOGICA, 2012, 97 : 525 - 526
  • [33] BENDAMUSTINE AND RITUXIMAB AS FIRST OR SECOND LINE THERAPY IN ELDERLY PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
    Gozzetti, A.
    Ciolli, S.
    Candi, V.
    Breschi, C.
    Fabbri, A.
    Schiattone, L.
    Cencini, E.
    Papini, G.
    Raspadori, D.
    Defina, M.
    Aprile, L.
    Bosi, A.
    Bocchia, M.
    HAEMATOLOGICA, 2014, 99 : 592 - 592
  • [34] Pure red cell aplasia complicating chronic lymphocytic leukemia: rapid response to high-dose methylprednisolone and rituximab
    Coleman, Niamh
    Murphy, Philip Thomas
    Thornton, Patrick
    Quinn, John
    LEUKEMIA & LYMPHOMA, 2013, 54 (10) : 2333 - 2335
  • [35] Does intensive treatment with high dose chlorambucil and prednisone as first line and cladribine as second line influence the survival of the patients with chronic lymphocytic leukemia?
    Robak, T
    Blonski, JZ
    Kasznicki, M
    LEUKEMIA & LYMPHOMA, 2001, 41 (5-6) : 545 - 557
  • [36] Chronic lymphocytic leukemia associated with immunotactoid glomerulopathy: a case report of successful treatment with high-dose methylprednisolone in combination with rituximab followed by alemtuzumab
    Castro, Januario E.
    Diaz-Perez, Julio A.
    Barajas-Gamboa, Juan S.
    Horton, John M.
    Weidner, Noel
    Kipps, Thomas J.
    LEUKEMIA & LYMPHOMA, 2012, 53 (09) : 1835 - 1838
  • [37] Rituximab in combination with high-dose dexamethasone for the treatment of relapsed/refractory chronic lymphocytic leukemia
    Smolej, Lukas
    Doubek, Michael
    Panovska, Anna
    Simkovic, Martin
    Brychtova, Yvona
    Belada, David
    Motyckova, Monika
    Mayer, Jiri
    LEUKEMIA RESEARCH, 2012, 36 (10) : 1278 - 1282
  • [38] FIRST LINE OF BENDAMUSTIN-RITUXIMAB TREATMENT IN PATIENTS WITH CHRONIC LYMPHATIC LEUKEMIA
    Adolfo, De la Fuente
    Maria Jose, Terol
    Antonio, Gutierrez
    Marta, Callejas
    Jose Antonio, Garcia Marco
    Maria Dolores, Garcia Malo
    Javier, De la Serna
    Gascon, Gonzalez
    Isabel, Marin
    Sanchis Laura, Garcia
    Monica, Ballesteros
    Celina, Benavente
    Isidro, Jarque
    Gullon Juliana, Ochoa
    Paola, Beneit
    Raquel, De Ona
    Carlos, Montalban
    Monica, Estevez
    Rebeca, Iglesias
    Elena, Prieto
    Antonio, Diaz-Lopez
    Patricia, Baltasar
    HAEMATOLOGICA, 2016, 101 : 199 - 199
  • [39] Obinutuzumab, High-Dose Methylprednisolone (HDMP), and Lenalidomide for the Treatment of Patients with Richter's Syndrome
    Heyman, Benjamin M.
    Choi, Michael Y.
    Kipps, Thomas J.
    CANCERS, 2022, 14 (24)
  • [40] Rituximab as first-line and maintenance therapy for patients with small lymphocytic lymphoma (SLL) and chronic lymphocytic leukemia (CLL).
    Hainsworth, JD
    Litchy, S
    Burris, HA
    Greco, FA
    BLOOD, 2001, 98 (11) : 363A - 363A
12345